Division of Vascular and Endovascular Surgery, University of Arizona Medical Center, Tucson, Ariz, USA.
J Vasc Surg. 2013 May;57(5):1299-305. doi: 10.1016/j.jvs.2012.10.112. Epub 2013 Feb 1.
Endovascular repair has emerged as a treatment option for popliteal artery aneurysms. Our goal was to analyze outcomes of elective and emergency endovascular popliteal artery aneurysm repair (EVPAR).
This was a retrospective review of clinical data of patients treated with EVPAR at our institution between 2004 and 2010. Stent-related complications, patency, outcome limb salvage, and survival were evaluated and analyzed.
EVPAR was performed in 31 limbs of 25 patients (mean age, 81 years; range, 65-89 years). Repair was elective in 19 limbs (61%) and emergent in 12 (39%). One aneurysm ruptured and 11 presented with acute thrombosis. All 11 underwent thrombolysis before EVPAR. Patients were implanted with a mean of 2.1 Viabahn stent grafts (range, 1-4). Ten procedures (32%) were performed percutaneously and 21 by femoral cutdown. Technical success was 97%. Overall 30-day mortality was 6.4%, with 0% in the elective group, and 16.7% in the emergent group (P = .14). Early complications included graft thrombosis in two limbs (6.4%) and hematoma in four (13%), all after percutaneous repair. Myocardial infarction and thrombolysis-associated intracranial hemorrhage occurred in one patient each (3.2%). The 30-day primary and secondary patencies were 93.6% and 96.7%, respectively, and were 100% in the elective group and 83.3% and 91.6%, respectively, for the emergent group. Mean follow-up was 21.3 months (range, 1-75 months). Primary patency at 1 year was 86% (95% for elective, 69% for emergent; P = .56), secondary patency at the same time was 91% (elective, 100%; emergent, 91%). One-year limb salvage was 97%. Two-year survival was 91% for the elective group and 73% for the emergent group (P = .15). Five stent occlusions were encountered after 30 days, four in the elective group. Four underwent successful reintervention, two had bypass, and two had thrombolysis, followed by angioplasty. The fifth patient was asymptomatic and nonambulatory and remains under observation. Stent graft infolding occurred in one limb (3.2%), with no clinical sequelae. No stent migration or separation was observed. One stent fracture was noted in an asymptomatic patient. Three (10%) type II endoleaks were detected but none had aneurysm expansion. One (3.2%) type I endoleak was treated percutaneously with placement of an additional stent graft. Overall, major adverse events, including death, graft occlusion with or without reoperation, or reoperation for endoleak or stent infolding occurred after 11 procedures (35.5%). On univariate analysis, no factors predicted stent failure, including runoff, antiplatelet therapy, emergency repair, number of stents implanted, heparin bonding of the stent, or degree of stent oversizing.
These results support elective EVPAR in anatomically suitable patients with increased risk for open repair; however, major adverse events after EVPAR, mainly after emergency repairs, are frequent. A prospective randomized multicenter study to justify EVPAR in the emergent setting is warranted.
血管腔内修复术已成为治疗腘动脉动脉瘤的一种治疗选择。我们的目标是分析择期和急诊血管内修复(EVPAR)治疗腘动脉动脉瘤的结果。
这是对 2004 年至 2010 年期间在我们机构接受 EVPAR 治疗的患者的临床数据进行的回顾性分析。评估和分析了支架相关并发症、通畅性、保肢效果和生存情况。
EVPAR 治疗了 25 名患者的 31 条肢体(平均年龄 81 岁;范围 65-89 岁)。19 条肢体(61%)为择期修复,12 条(39%)为急诊修复。1 个动脉瘤破裂,11 个出现急性血栓形成。所有 11 个在接受 EVPAR 前均进行了溶栓治疗。患者平均植入 2.1 个 Viabahn 支架(范围 1-4 个)。10 例(32%)经皮进行,21 例经股动脉切开进行。技术成功率为 97%。总的 30 天死亡率为 6.4%,择期组为 0%,急诊组为 16.7%(P=.14)。早期并发症包括 2 条肢体(6.4%)的支架血栓形成和 4 条肢体(13%)的血肿,均发生在经皮修复后。1 例患者发生心肌梗死和溶栓相关颅内出血(各 3.2%)。30 天的一期和二期通畅率分别为 93.6%和 96.7%,择期组分别为 100%和 83.3%和 91.6%,急诊组分别为 91%。平均随访时间为 21.3 个月(范围 1-75 个月)。1 年的一期通畅率为 86%(择期组为 95%,急诊组为 69%;P=.56),同期的二期通畅率为 91%(择期组为 100%,急诊组为 91%)。1 年的保肢率为 97%。择期组 2 年生存率为 91%,急诊组为 73%(P=.15)。30 天后有 5 例支架闭塞,其中 4 例发生在择期组。4 例患者成功再介入,2 例患者行旁路手术,2 例患者行溶栓后血管成形术。第 5 例患者无症状且无法行走,仍在观察中。1 条肢体(3.2%)出现支架折叠,无临床后遗症。未观察到支架迁移或分离。1 例无症状患者出现支架断裂。3 例(10%)发现 II 型内漏,但无动脉瘤扩张。1 例(3.2%)I 型内漏经皮用额外的支架移植治疗。总的来说,11 例(35.5%)患者发生了重大不良事件,包括死亡、支架闭塞伴或不伴再手术、或因内漏或支架折叠而再次手术。单因素分析显示,没有任何因素可预测支架失败,包括流出道、抗血小板治疗、急诊修复、植入支架数量、支架肝素结合或支架过度扩张程度。
这些结果支持在解剖上适合且开放修复风险增加的患者中进行择期 EVPAR;然而,EVPAR 后,特别是急诊修复后,主要不良事件较为常见。有必要进行前瞻性随机多中心研究,以证明在紧急情况下进行 EVPAR 的合理性。